Cycloplegic Refraction in Pediatric Patients With Esotropia
Cycloplegia, Refractive Errors, Esotropia
About this trial
This is an interventional treatment trial for Cycloplegia focused on measuring Vision, refractive error, cycloplegic agent, cycloplegia, esotropia, tropicamide, cyclopentolate
Eligibility Criteria
Inclusion Criteria: Alignment: subjects with esotropia Age: 3-16 years Brown irides; grade 4 and 5 using iris color classification system developed by Seddon et al Duration: 2 different visits ≥ 1 week apart within 3 months Exclusion Criteria: Abnormal red reflex (e.g., media opacity) History of heart or neurological diseases History of developmental delay History of a previous allergy to cycloplegic agents Presence of syndromes (e.g., Down's syndrome) History of intraocular surgery
Sites / Locations
- Yarmouk UniversityRecruiting
- Hamad Medical Corporation
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Cyclopentolate arm
Tropicamide arm
To study the effect of cyclopentolate 1% for cycloplegic refractions in pediatric populations with ET: Firstly, we instilled an anesthetic drop into patients' eyes. Secondly, 2 drops of cyclopentolate 1% (cyclogel) 5 minutes apart were instilled. Autorefraction was taken at 60 minutes after first drop instillation. Primary outcome: spherical equivalent (SE) of cycloplegic refraction at 60 minutes.
To study the effect of tropicamide 1% for cycloplegic refractions in pediatric populations with ET: Firstly, we instilled an anesthetic drop into patients' eyes. Secondly, 2 drops of tropicamide 1% (mydriacil) 5 minutes apart were instilled. Autorefraction was taken at 30 minutes after first drop instillation. Primary outcome: spherical equivalent (SE) of cycloplegic refraction at 30 minutes.